Most Liquid Dow Jones Biotechnology Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1ABBV AbbVie Inc
11.88 B
 0.15 
 1.39 
 0.22 
2AMGN Amgen Inc
11.48 B
 0.18 
 1.52 
 0.27 
3VRTX Vertex Pharmaceuticals
9.77 B
 0.23 
 1.50 
 0.34 
4REGN Regeneron Pharmaceuticals
7.02 B
(0.08)
 2.06 
(0.17)
5GILD Gilead Sciences
6.14 B
 0.17 
 1.59 
 0.26 
6BIIB Biogen Inc
4.91 B
(0.04)
 1.74 
(0.07)
7INCY Incyte
2.72 B
(0.08)
 2.20 
(0.18)
8ALNY Alnylam Pharmaceuticals
2.27 B
 0.07 
 3.03 
 0.22 
9UTHR United Therapeutics
2.26 B
(0.10)
 2.29 
(0.22)
10IONS Ionis Pharmaceuticals
2.04 B
(0.08)
 2.65 
(0.22)
11ILMN Illumina
2.01 B
(0.28)
 2.73 
(0.76)
12NVAX Novavax
1.28 B
(0.02)
 4.70 
(0.12)
13BMRN Biomarin Pharmaceutical
1.27 B
 0.07 
 1.63 
 0.12 
14AGIO Agios Pharm
819.31 M
(0.07)
 2.64 
(0.18)
15NBIX Neurocrine Biosciences
799.4 M
(0.10)
 2.83 
(0.28)
16ALKS Alkermes Plc
580.97 M
 0.11 
 1.93 
 0.22 
17RARE Ultragenyx
542.8 M
(0.10)
 2.47 
(0.24)
18ACAD ACADIA Pharmaceuticals
436.35 M
 0.00 
 2.82 
 0.01 
19TECH Bio Techne Corp
247.03 M
(0.15)
 2.16 
(0.32)
20CRL Charles River Laboratories
233.91 M
(0.10)
 2.35 
(0.24)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).